Indian Pharma: Margin Squeeze Ahead Despite Revenue Growth

Indian pharmaceutical companies are poised for a significant contraction in profitability during the first quarter of fiscal year 2026-27, despite an anticipated rise in overall revenues. This structural margin compression, as outlined in a recent Goldman Sachs report, stems from a challenging combination of an unfavorable product mix and persistently elevated input costs, including raw materials and freight charges. These factors, exacerbated by the ongoing Middle East conflict, are expected to drive a sector-wide margin decline of approximately 185 basis points year-on-year for the June quarter.

A critical component of this pressure emerges from the US generics market, where Goldman Sachs expresses caution, particularly for Indian firms heavily exposed to this segment. The absence of high-margin gRevlimid revenues, which previously provided a significant boost, is a key concern. While the US generics business currently shows a relatively stable pricing environment, with injectables noting a monthly increase in price erosion, the firm views the overall opportunity as tactical. Pricing pressure is projected to normalize to mid-to-high single digits in the medium term, influenced by easing shortages and increasing market concentration, thereby limiting long-term upside.

Conversely, the domestic Indian Pharmaceutical Market (IPM) demonstrated robust performance, recording approximately 11.6 percent growth in Q1. This resilience was underpinned by improved volume expansion, healthy pricing, which saw a 5.8 percent year-on-year increase, and strategic introductions of new products, notably Semaglutide. This highlights a divergence in market dynamics, with domestic demand acting as a partial offset to international headwinds.

For Contract Development and Manufacturing Organisations (CDMOs), the outlook for FY27 appears mixed. This variability is attributed to differing product approval timelines and the cyclical nature of inventory destocking. Consequently, investors are advised to closely monitor new product launches throughout FY27 as companies strategically seek fresh avenues for growth to counteract the prevailing structural challenges.

The overarching thesis is clear: the Indian pharmaceutical sector is navigating a period where underlying cost structures and shifting product portfolios are exerting downward pressure on profitability. While revenue growth may persist, the ability to translate that into enhanced bottom-line performance will hinge on strategic product diversification and the successful management of a complex global supply chain, rather than relying on previous high-margin opportunities.